-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 KNgzM496MjF+U9e1Lr7/uIvBWdqqUZ0D992jeLWQ63eO4q9Lhpq5N9w8mqXukowb
 sK4DB3VR41FVM3Gve0FbEw==

<SEC-DOCUMENT>0001144204-08-037561.txt : 20080630
<SEC-HEADER>0001144204-08-037561.hdr.sgml : 20080630
<ACCEPTANCE-DATETIME>20080630163534
ACCESSION NUMBER:		0001144204-08-037561
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20080630
FILED AS OF DATE:		20080630
DATE AS OF CHANGE:		20080630

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XTL BIOPHARMACEUTICALS LTD
		CENTRAL INDEX KEY:			0001023549
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51310
		FILM NUMBER:		08926261

	BUSINESS ADDRESS:	
		STREET 1:		711 EXECUTIVE BOULEVARD
		STREET 2:		SUITE Q
		CITY:			VALLEY COTTAGE
		STATE:			NY
		ZIP:			10989
		BUSINESS PHONE:		972-8-930-4440

	MAIL ADDRESS:	
		STREET 1:		711 EXECUTIVE BOULEVARD
		STREET 2:		SUITE Q
		CITY:			VALLEY COTTAGE
		STATE:			NY
		ZIP:			10989
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v118606_6k.htm
<TEXT>
<html>
  <head>
    <title>
      Unassociated Document
</title><!-- Licensed to: vfvf-->
<!-- Document Created using EDGARizer HTML 3.0.4.0 -->
<!-- Copyright 2006 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff"><br>
    <div>&#160;</div>
    <div>&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <IMG SRC="logo.jpg"></div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
      <hr style="COLOR: black" align="center" noshade size="1" width="100%">
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>UNITED
      STATES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
      AND EXCHANGE COMMISSION</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington,
      D.C. 20549</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Form
      6-K</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Report
      of Foreign Private Issuer</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Pursuant
      to Rule 13a-16 or 15d-16 </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>of
      the Securities Exchange Act of 1934</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      June
      30, 2008</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commission
      File Number: </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>000-51310</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>XTL
      Biopharmaceuticals Ltd.</u></strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
      of registrant's name into English)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>711
      Executive Blvd., Suite Q</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Valley
      Cottage, New York 10989</u></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
      of principal executive offices)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether the registrant files or will file annual reports under
      cover Form 20-F or Form 40-F.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
      20-F
<font style="DISPLAY: inline; FONT-FAMILY: Wingdings">x</font></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
      40-F
<font style="DISPLAY: inline; FONT-FAMILY: Wingdings">o</font></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(1): <font style="DISPLAY: inline; FONT-FAMILY: Wingdings">o</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(7): <font style="DISPLAY: inline; FONT-FAMILY: Wingdings">o</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether by furnishing the information contained in this Form,
      the
      registrant is also thereby furnishing the information to the Commission pursuant
      to Rule 12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes
<font style="DISPLAY: inline; FONT-FAMILY: Wingdings">o</font></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">No
<font style="DISPLAY: inline; FONT-FAMILY: Wingdings">x</font></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
&#8220;Yes&#8221;
      is marked, indicate below the file number assigned to the registrant in
      connection with Rule 12g3-2(b): 82-</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>
      N/A
</u></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Incorporation
      by Reference: This Form 6-K of XTL Biopharmaceuticals Ltd. dated June 30, 2008
      is hereby incorporated by reference into the registration statements on Form
      F-3
      (File No. 333-141529 and File No. 333-147024) filed by XTL Biopharmaceuticals
      Ltd. with the Securities and Exchange Commission on March 23, 2007 and October
      30, 2007, respectively, </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>and
      the registration statements on Form S-8 (File No. 333-148058 and File No.
      333-148574) filed by XTL Biopharmaceuticals Ltd. with the Securities and
      Exchange Commission on December 14, 2007 and January 18, 2008,
      respectively</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>XTL
      Biopharmaceuticals Announces Completion of Patient Randomization into the
      Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic
      Pain </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Valley
      Cottage, New York, June 30, 2008 </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-
      XTL
      Biopharmaceuticals Ltd. (NASDAQ: XTLB; TASE: XTL) today announced that it has
      completed patient randomization into its Phase 2b study of Bicifadine - a
      serotonin and norepinephrine reuptake inhibitor (SNRI) - for the treatment
      of
      diabetic neuropathic pain. 350 patients were randomized into the study. Based
      on
      the completion of randomization, the Company expects to have the last patient
      complete the study in the next 4 months.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Phase
      2b trial is aimed at demonstrating the efficacy of Bicifadine in diabetic
      neuropathic pain, using a study design that is similar to the successful
      registration trials of Cymbalta&#174;, a member of the SNRI class that is approved
      for this indication, and other approved agents for neuropathic pain.
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Phase
      2b study is a randomized, double-blind, placebo-controlled study comparing
      200mg
      3x/day (tid) and 400mg 3x/day (tid) of Bicifadine versus placebo, with a 1:1:1
      randomization between the three arms, in patients with diabetic neuropathic
      pain. Approximately 40 clinical centers in the United States, Germany, Israel
      and India are participating in the study. Following randomization, all patients
      enter a 2-week titration period to allow them to gradually escalate up to their
      target treatment dose. This is followed by a 12-week steady-state treatment
      period at the target treatment dose. The primary endpoint of the study is to
      compare the efficacy of each of the two active doses of Bicifadine (200mg tid
      and 400mg tid) versus placebo in reduction of pain associated with diabetic
      neuropathy, at baseline (at the time of randomization) versus week 14 (week
      12
      of the steady-state phase). Pain is measured based on a 24-hour pain rating
      using the 11-point Pain Intensity Numeric Rating Scale (formerly referred to
      as
      the LIKERT scale). </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Bicifadine
      is being developed for the treatment of diabetic neuropathic pain which
      represents a significant unmet medical need in the rapidly growing multi-billion
      dollar neuropathic pain market. Bicifadine is a member of the SNRI drug class,
      a
      proven class in the treatment of diabetic neuropathic pain. Bicifadine&#8217;s
      efficacy in reducing pain has been demonstrated in over 15 clinical trials
      in
      acute pain, and its safety profile has been established in over 3,000 patients.
      Importantly, Bicifadine has a unique ratio of reuptake inhibition of serotonin
      versus norepinephrine, which differentiates it from other members of the SNRI
      drug class. </font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ron
      Bentsur, XTL&#8217;s Chief Executive Officer, commented, &#8220;We are very excited to have
      completed this milestone of patient randomization ahead of our projected
      timeline, and we remain grateful for the tremendous dedication of the
      investigators who are participating in the study.&#8221; Mr. Bentsur added, &#8220;We
      eagerly await the outcome of this study in Q4 2008.&#8221;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">XTL
      in-licensed the world-wide rights to Bicifadine from Dov Pharmaceutical, Inc.
      (NASDAQ OTC: DOVP) in January 2007.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ABOUT
      XTL BIOPHARMACEUTICALS LTD.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">XTL
      Biopharmaceuticals Ltd. (&#8220;XTL&#8221;) is engaged in the development of therapeutics
      for the treatment of diabetic neuropathic pain and HCV. XTL is developing
      Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment
      of diabetic neuropathic pain, which is currently in a Phase 2b study. XTL has
      out-licensed its novel pre-clinical HCV small molecule inhibitor program. XTL
      also has an active in-licensing and acquisition program designed to identify
      and
      acquire additional drug candidates. XTL is publicly traded on the NASDAQ and
      Tel-Aviv Stock Exchanges (NASDAQ: XTLB; TASE: XTL).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Contact:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ron
      Bentsur, Chief Executive Officer</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
      +1-(845)-267-0707 ext. 225</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Cautionary
      Statement</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Some
      of the statements included in this press release, particularly those
      anticipating future clinical and business prospects for our clinical compound
      for neuropathic pain, Bicifadine, the likelihood of successful results from
      a
      clinical trial with Bicifadine, operating strategies and similar matters, may
      be
      forward-looking statements that involve a number of risks and uncertainties.
      </em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>For
      those statements, we claim the protection of the safe harbor for forward-looking
      statements contained in the Private Securities Litigation Reform Act of 1995.
      Among the factors that could cause our actual results to differ materially
      are
      the following: our ability to successfully complete the Phase 2b clinical trial
      with Bicifadine and obtain positive trial results from the Phase 2b clinical
      trial, all of which will directly impact our ability to continue to fund our
      operations; and other risk factors identified from time to time in our reports
      filed with the Securities and Exchange Commission, including our annual report
      on Form 20-F filed with the Securities and Exchange Commission on March 27,
      2008. Any forward-looking statements set forth in this press release speak
      only
      as of the date of this press release. We do not intend to update any of these
      forward-looking statements to reflect events or circumstances that occur after
      the date hereof. This press release and prior releases are available at
      http://www.xtlbio.com. The information in our website is not incorporated by
      reference into this press release and is included as an inactive textual
      reference only. </em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to the requirements of the Securities Exchange Act of 1934, as amended, the
      registrant has duly caused this report to be signed on its behalf by the
      undersigned, thereunto duly authorized.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
      <table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">

          <tr valign="top" bgcolor="#ffffff">
            <td width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: "><strong>XTL
              BIOPHARMACEUTICALS LTD.</strong></font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">Date:&#160;June
              30, 2008</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">By:&#160;&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">/s/&#160;Ron
              Bentsur </font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="FONT-FAMILY: " size="1">&#160;</font></td>
            <td align="left">
              <hr style="COLOR: black" align="left" noshade size="2" width="80%"><font size="2">Ron
              Bentsur </font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Chief
                Executive Officer </font></div>
            </td>
          </tr>

      </table><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`!!`+`#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^@D`9-<;
M\2;CQ'I_AEM4\.7QMY;,E[B/RT</%CDC<IY7@]1QNZ\5X_H_QA\46^KVLFJZ
MA]KT\2`7$/V:(%D/!P54'('(Y'(YXK>GAY5(\T3&=>,)<K-B\^/&K_VK(UCI
MEE_9PD&Q)E;S2GNP;`)Y['&>^,GV7PWKL'B7P[9:Q;J42YCW%"<[&!(9<X&<
M,",XYQFO!KSX-Z^^J*-(>UO=)G^>"^^T+M$9SM+=R<8.5!'/%6/$/C/4O`KV
MOA+POJO[C2XRES<F&-S-.S%WQG<`JEL8X(.X'.,UT5*5.:2I;F$*LX-NIL?0
MU%>5?"K6?&/BB6XU36-5=]+@S''&((5\Z3'.2%W84$'C&21R<$5YI_PMOQQ_
MT&__`"4@_P#B*PCAI2DXIK0V>(BDI-/4^H**^7_^%M^./^@W_P"2D'_Q%'_"
MV_''_0;_`/)2#_XBK^I5.Z(^MP[,^H**^7_^%M^./^@W_P"2D'_Q%'_"V_''
M_0;_`/)2#_XBCZE4[H/K<.S/J"BLOPS>3ZAX5TB]NI/,N+BRAEE?`&YF0$G`
MX')/2M2N5JSL=*=U<**Y?QWJ]]HVAP7.GS^3*URL9;8K94JQQR#W`J]X2O[G
M5/#%G>7<GF3R;][[0N<.P'`XZ`5HZ,E257I>Q@L3!UW0ZI7\C:HHHK(Z`HK@
MM5UOQ#!XZ2QMGF&G&>%2!;J5VD+N^;;GN>]=[6M2DX)-O=7,*.(C5E**37*[
M:_H%%%%9&X4444`%?+OQ+\'CPCXH:.UC9=,NQYMJ22VW^\F2.JGZ_*5R<DU]
M15RWQ"\.V_B7P=>6L\\5NT`^TQ3RDA(G0'EL=L%@3S@$G&16^'J^SGY,QKT^
M>/FCRKPS\56T?X;W>FRRL=5M1Y.GLP))5NAR<C]WSP0!@*M>?^'-!O?%7B"W
MTVV$C/,X,TH7=Y29^:0\CIGUY.!U(K(KZ%^"6B:=;>%6UB)H9M0NY'25P/GA
M53@1=3CH'[9W+G.`:[ZCC1BY16K.*FI5I*+>B/0M(TFUT31[72[)-MM;1B->
M`"?5C@`9)R2>Y)-4O^$-\+_]"WI'_@#%_P#$UMT5Y7,][GI<J['@_P`<=&TO
M2?[!_LW3;.R\W[1YGV:!8]^/+QG:!G&3^=9'P7TVPU7QA>0:C8VUY"M@[A+B
M)9%#>9&,@$$9P3S[UTO[0/\`S+O_`&\_^TJQ/@1_R/%[_P!@U_\`T9%7HQ;^
MK7_K<X))?6+?UL>U'P;X7/\`S+>D?^`,7_Q-?(M?:M?%53@FWS7\BL6DK6/K
MKP9_R(^@?]@ZW_\`1:UMUB>#/^1'T#_L'6__`*+6MNN&?Q,[(_"CBOB?_P`B
MU;?]?B_^@/5+1_%=EX;\#::LJF:[=96C@0X)_>/@L?X1GC//L#@U=^)__(M6
MW_7XO_H#UF_#SPU:7-A+JFH6L<V]]D"RJ&7:.K8Z')XY'&WWKT8*G]43J;)_
M>>'5]M_:,E1W<=WT6FH^#XJ1-,HGTEXXCG<T<X=AQV!`SS[BNWTO5;+6;,7=
MC.LL18J2`001U!!Y'^!!Z&H-4\/:9J]J\-S:199-BRJ@#ICIM;MC\J\Z\#W-
MQHWC*72'*LDKO!*0<`,FXAAQST([=?:L_9T:U.4J2LX]-S=5\3AJT(5Y*49:
M7M9IG;W?C*PL_$*Z*\-PURTB1AE5=F7QCG.>X[5OO(D4322.J(H+,S'``'4D
MUY1K7_)68O\`K\MOY)6Q\3=8>*WMM'BDQYR^;.,'.T'Y!GT)!_(=CR2PJE*G
M&/VE=A',91C6G4VA*R+6I_$S3K64QV-M)>8/+D^6A^A()/Y"H;+XHVDLX2]T
M^2WC.!YB2>9CGN,#@#GC)XZ5H^"?#%MIFD07EQ;HU_.OF%V&3&#G"C/W>#S[
MYY/%:/B3PU9:]8RAX8UO=F(;C&&!&2`3C)7).1[GO0WA8RY.5V[W_0(QS"4/
M:\ZOORVT]+[FK9W<%_:175K*LL,J[E=>A_SZ5/7E_P`-]4DLM5N-$N`4$Q9U
M1EP5E488=/0=_P"[7J%<V(H^QGRG;@L4L31539]?4*\4^-?C3)_X12QDZ;7U
M`F/_`'7C0$_@QP/[O/WA7HWCKQ7'X/\`#,VH[5DN6(BMHV!VM(<XSCL`"3TS
MC&02*^7;&SOO$&MPVD3//>WLV-\A+%F8\LQY/J2?J:VPE*[YY;(6)J67(MV6
MK+PQJNH>'+[7;:W,EE92*DI'7D9)`[A<KGTW`],D;OPS\9_\(AXC!N9"NEW>
M([H!-Q7&=KCOP3SUX)X)Q7T1H7AVST3PM;:`$2>VB@,4H=<K*6SO)4D\,2QQ
MDCG'2OF/QMX8E\)>*+K3&+-!GS+:1CDO$V=I/3D8(/'4&NBG5C7YH,QG2E1M
M-'UI17EGP8\8G5M';0+R0M>6"[H6.27@R`.<]5)QVX*XZ&O4Z\ZI!PDXL[H3
M4X\R/%?V@?\`F7?^WG_VE6)\"/\`D>+W_L&O_P"C(JV_V@?^9=_[>?\`VE6)
M\"/^1XO?^P:__HR*NZ/^Z_UW..7^\_UV/H6OBJOM6OBJIP/VOD5C/L_,^NO!
MG_(CZ!_V#K?_`-%K6W7SAIGQH\1:5I5IIT%EI30VL*0(7BD+%5``SA^N!5K_
M`(7OXH_Y\-'_`._,O_QRLY86HVV:+$TTK'J'Q/\`^1:MO^OQ?_0'K2\!_P#(
MEZ?_`-M/_1C5XS+\2M9\9*-.U&VL(H8SYX-O&ZMN'R_Q,>,,:[WP/XNMM,M?
M[(U1F@"L&AD8?*`^#@^GWMP)XP>W%=,L/4^JJ*6J=SREB:<<R<I.R<;'IE>.
M6L,D_P`4&2!MC#4I)"1Z*Y9A^(!'XUW^L>-='TRS,D5W#=S,#LB@<-D^Y'`'
M^1FN4^'NES:AK,^O7.<(S;6Z;I&^\?P!/Y^U9X:$J5.=2>BM9&N.J1KUZ5&F
M[M.[\DBIK7_)68O^ORV_DE'Q._Y&6WS_`,^:?^AO1K7_`"5F+_K\MOY)71?$
M;0GOM,CU.`)OLU/FC;\S1G'.?]GD_0D_7IC-0J47+^4X)TI5:.)4-U._XG;(
MRLBLI!4C(([TZN!\%^-+'^S(=-U*=;>>`"..23A'0#CGH"`,<]>.I-:'B/QS
MINGV,L6GW27-ZZ8C\DAE3.?F+<CCTZ].QS7G/"U54]FD>W#,,/*C[9R5OQ]#
ME-#(/Q8E]/MES_*2O6:\V^&NA/YDNM3H-N#%`&7DG^)AD?AD?[5>DUKCYIU%
M%?95C#*(2C0<I*W,VS!U_P`&:!XHN(9]9LGNGA0I&#<2HJ@G)PJL!D]SC)P/
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M<5_PJ3P/_P!`3_R;G_\`BZ/^%2>!_P#H"?\`DW/_`/%UVM%5[6I_,_O%[*'9
M'(6OPO\`!UE*9+?1]CD;2?M,QX_%_:M+4?"&C:G:PP36Q7R(A%#(CD.BCH,]
M_P`<]_6MVBCVU3?F?WD2PU&5[P6ODCC[7X:Z%;RAY&N[E0,;)9``3Z_*`:ZR
M""*VA6*&-(XU&%1%``'T%2445*TZGQNX4</2H_PXI&1/X9TBYU8:I+:;KT.K
MB3S'&&7&TX!QV':M?%%%3*4I6N]BXTX0;<4E?<YC4O`6A:C*91`]JY.2;9@H
M/']T@@?@!45E\.M!M)1(Z3W1!!"SR<`@YZ*!GZ'(KK**T6(JJ/+S.Q@\%AG+
MG<%?T&QQI%&L<:*B(`JJHP`!T`%.HHK$Z@HHHH`****`"BBB@`HHHH`****`
;"BBB@`HHHH`****`"BBB@`HHHH`****`/__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
